This substudy aims to identify cases of tuberculosis after the CoVPN 3008 clinical trial is completed.
This observational substudy will involve participants from the CoVPN 3008 trial, regardless of their HIV status, to study tuberculosis (TB). At the start, all participants will be screened for TB, even if they have no symptoms. They will receive chest x-rays and provide sputum samples for TB testing using Xpert Ultra, smear microscopy, and culture. The study has two main groups. Group 1 includes participants with confirmed TB, and Group 2 includes participants without TB who will act as controls. Participants with confirmed TB will start treatment and have a first follow-up visit on Day 4 to reassess TB symptoms and collect blood samples. A second follow-up visit will take place at week 26 to evaluate their treatment progress, clinical outcomes, and TB status, ensuring they receive the necessary care. Participants without TB will have a single follow-up visit on Day 4 to reassess TB symptoms and collect blood samples. The study aims to identify potential biomarkers of TB by analyzing blood samples from both cases and controls, focusing on gene expression linked to TB, including hidden (subclinical) TB.
Study Type
OBSERVATIONAL
Enrollment
5,694
Participants will undergo an abbreviated physical exam, assessment of concomitant medications, and reassessment for signs/symptoms of TB
Peripheral blood samples, including serum, PBMC, and whole blood, are collected from participants. A tongue swab is also collected from each participant.
Participants will undergo another complete physical exam and have their medical (including TB) history, potential TB signs/symptoms, and concomitant medications reassessed. Chest radiography will be obtained for all participants. An assessment of TB outcomes will also be performed.
Proportion of participants with TB
The 95% confidence interval on the proportion of participants with TB will be estimated using the "score" method
Time frame: Measured at Day 1, Day 4 and week 26
Association parameters of each demographic variable with confirmed TB.
Proportions and 95% CIs will be estimated using the score method. A multivariate analysis will also be conducted using generalized linear regression models with TB as the outcome.
Time frame: Measured at Day 1, Day 4 and week 26
Proportion of participants with confirmed TB at the six-month follow visit out of the total number of participants that are screened at the six-month visit and who had confirmed TB at their enrollment visit.
Proportion and 95% CI will be estimated using the score method.
Time frame: Measured at Day 1, Day 4 and week 26
Peripheral blood biomarkers associated with diagnosis of TB, including subclinical TB.
TB risk scores will be computed from RNA sequencing data generated from each participant's baseline whole-blood sample (Tempus tube) provided upon enrollment into CoVPN 3008. Association of each score with confirmed TB will be assessed using cross-validated ROC curve analysis with area under curve (AUC) 95% CI estimated using the Delong method.
Time frame: Measured at Day 1, Day 4 and week 26
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Peripheral blood samples, including serum, PBMC, and whole blood, will be collected. Participants not previously identified as living with HIV will undergo HIV diagnostic testing, while participants living with HIV will have their HIV viral load and CD4+ T-cell count measured.
Gaborone CRS
Gaborone, Botswana
Eswatini Prevention Center CRS
Mbabane, Eswatini
Moi University Clinical Research Centre
Eldoret, Kenya
Kisumu Crs
Kisumu, Kenya
Kombewa Clinical Research Center
Kisumu, Kenya
Blantyre CRS
Blantyre, Malawi
Malawi CRS
Lilongwe, Malawi
Synergy Biomed Research Institute
East London, Eastern Cape, South Africa
Nelson Mandela Academic Research Unit CRS
Mthatha, Eastern Cape, South Africa
PHOENIX Pharma (Pty) Ltd
Port Elizabeth, Eastern Cape, South Africa
...and 31 more locations